Analysis of CYP2C9*5 in Caucasian, Oriental and Black-African populations

European Journal of Clinical Pharmacology

Volumn 58, Issue 8, 2002, Pages 555-558

  Yasar, Ümit ^a,b   Aklillu, Eleni ^c   Canaparo, Roberto ^a   Sandberg, Mia ^a   Sayi, Jane ^d   Roh, Hyung Keun ^a,e   Wennerholm, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b HACETTEPE UNIVERSITY   (Turkey)

^c KAROLINSKA INSTITUTE   (Sweden)

^d MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^e Inha University Hospital   (South Korea)

Author keywords

CYP2C9 polymorphism; CYP2C9*5

Indexed keywords

CYTOCHROME P450 2C9; DNA; ENDONUCLEASE; PRIMER DNA; WARFARIN; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; ASIAN; ASSAY; BINDING SITE; CAUCASIAN; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME METABOLISM; ENZYME POLYMORPHISM; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYDROXYLATION; NEGRO; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RACE; RACE DIFFERENCE; SAMPLING; TECHNIQUE; AMINO ACID SEQUENCE; DNA SEQUENCE; GENETICS; MOLECULAR GENETICS; POINT MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; AMINO ACID SEQUENCE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HUMANS; MOLECULAR SEQUENCE DATA; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE ANALYSIS, DNA;

EID: 0036835320     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0518-6     Document Type: Article

References (33)

1. Yasar Ü (2002) Cytochrome P450 2C9 polymorphism: Inter-individual differences and phenotyping methodology (thesis). Repro Print AB, Stockholm
2. Fleming I (2001) Cytochrome p450 and vascular homeostasis. Circ Res 89:753-762
3. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349
4. Scordo MG, Aklillu E, Yasar Ü, Dahl M-L, Spina E, Ingelman-Sundberg M (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a Black-African population. Br J Clin Pharmacol 52:447-450
5. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429-439
6. Gaedigk A, Leeder JS, Sellers EM, Tyndale RF (2000) Cytochrome P450 CYP2C9 allele frequencies in Canadian Native Indians (CNI) (abstract). Clin Pharmacol Ther 67:OIII-A3, 168
7. Yasar Ü, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F (1999) Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628-631 [erratum Biochem Biophys Res Commun (1999) 258:227]
8. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS (2001) Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 79:841-847
9. Wang SL, Huang J, Lai MD, Tsai JJ (1995) Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5:37-42
10. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG (2001) Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 51:277-280
11. Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E, Yamane M, Fukumaki Y, Ninomiya H, Tashiro N, Otsubo K, Higuchi S (2000) Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: Genetic analysis of the CYP2C9 locus. Pharmacogenetics 10:85-89
12. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 60:382-387
13. Strom A, Bradford L, Rettie A, Leeder J, Gaedigk A (2000) Allele frequency of new CYP2C9 allele (CYP2C9*4) in Caucasians and African Americans (AA). Drug Metab Rev 32:137-140
14. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA (2001) Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11:803-808
15. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90
16. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719
17. Brandolese R, Scordo M, Spina E, Gusella M, Padrini R (2001) Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 70:391-394
18. Thijssen HH, Drittij MJ, Vervoort LM, de Vries-Hanje JC (2001) Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clin Pharmacol Ther 70:292-298
19. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9:71-80
20. Brockmöller J, Kirchheiner J, Bauer S, Prang V, Rohde W, Roots I (2001) Impact of CYP2C9 genotype on glibenclamide pharmacokinetics and pharmacodynamics in healthy volunteers (abstract). Pharmacol Toxicol 89:107
21. Miners JO, Birkett DJ (1998) Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538
22. Kerb R, Aynacioglu A, Brockmöller J, Schlagenhaufer R, Bauer S, Szekeres T, Hamwi A, Fritzer-Szekeres M, Baumgartner C,Öngen H, Güzelbey P, Roots I, Brinkmann U (2001) The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 1:204-210
23. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M (1996) S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 6:521-526
24. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L (1996) Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6:441-447
25. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L (1996) CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6:547-551
26. Wennerholm A, Johansson I, Massele AY, Lande M, Alm C, Aden-Abdi Y, Dahl ML, Ingelman-Sundberg M, Bertilsson L, Gustafsson LL (1999) Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics 9:707-714
27. Wennerholm A, Dandara C, Sayi J, Svensson JO, Abdi YA, Ingelman-Sundberg M, Bertilsson L, Hasler J, Gustafsson LL (2002) The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 71:77-88
28. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M (1996) Frequent distribution of ultra-rapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441-446
29. Sunnucks P, Wilson AC, Beheregaray LB, Zenger K, French J, Taylor AC (2000) SSCP is not so difficult: The application and utility of single-stranded conformation polymorphism in evolutionary biology and molecular ecology. Mol Ecol 9:1699-1710
30. Hayashi K, Yandell DW (1993) How sensitive is PCR-SSCP? Hum Mutat 2:338-346
31. Yasar Ü, Forslund C, Tybring G, Dorado P, Llerena A, Sjöqvist F, Eliasson E, Dahl M-L (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89-98
32. Yasar Ü, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, Eliasson E (2001) Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 29:1051-1056
33. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I (2002) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71:286-296